Lintuzumab Bi-213

Drug Profile

Lintuzumab Bi-213

Alternative Names: Anti-CD33 monoclonal antibody M195 Bi-213; Bi213 MOAB M195; Bi213 monoclonal antibody M195; Bismab-A; Bismuth-213 HuM195; Bismuth-213 lintuzumab; Bismuth-213-labelled HuM195; HuM195-Bi-213; Lintuzumab bismuth-213; Monoclonal antibody M195 Bi-213 conjugate; Monoclonal antibody M195 bismuth-213; SMART M195 bismuth-213

Latest Information Update: 17 Jun 2013

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD33 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 17 Jun 2013 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA (IV)
  • 13 Jun 2012 Clinical development is ongoing in USA
  • 09 Dec 2008 Adverse events and efficacy data from a phase I/II trial in Acute myeloid leukaemia presented at the 50th Annual Meeting and Exposition of the American Society of Hematology (ASH-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top